Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles

American Journal of PharmTech Research Pub Date : 2019-10-08 DOI:10.46624/ajptr.2019.v9.i5.002

Manisha Patel, G. Saraogi, Shailesh Sharma

{"title":"Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles","authors":"Manisha Patel, G. Saraogi, Shailesh Sharma","doi":"10.46624/ajptr.2019.v9.i5.002","DOIUrl":null,"url":null,"abstract":"Please cite this article as: Patel M et al., Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles . American Journal of PharmTech Research 2019. Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles Manisha Patel , Gaurav K. Saraogi, Shailesh Sharma 1.NIMS Institute of Pharmacy, NIMS University , Sobha nagar New Delhi Highway, Jaipur303121 (Rajasthan) 2.NMIMS, School of Pharmacy and Technology Management, Shirpur Maharashtra India ABSTRACT Tuberculosis is a ubiquitous, highly contagious chronic granulamatous communicable bacterial infectious disease caused by Mycobacterium tuberculosis and other species of same genera. “Rifabutin” which is useful in the management of tuberculosis. Formulated Rifabutin in the form of solid lipid nanoparticle evaluated for their efficacy ex-vivo by checking for various interactions. Thus, physiological parameters like cellular uptake, MTT cytotoxicity assay and hemolytic toxicity of rifabutin loaded mannosylated solid lipid nanoparticles are determined and compared. The present work establishes the suitability of rifabutin loaded mannosylated solid lipid nanoparticles as a delivery system.","PeriodicalId":7701,"journal":{"name":"American Journal of PharmTech Research","volume":"35 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of PharmTech Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46624/ajptr.2019.v9.i5.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Please cite this article as: Patel M et al., Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles . American Journal of PharmTech Research 2019. Ex-Vivo Efficacy of Rifabutin Loaded Solid Lipid Nanoparticles Manisha Patel , Gaurav K. Saraogi, Shailesh Sharma 1.NIMS Institute of Pharmacy, NIMS University , Sobha nagar New Delhi Highway, Jaipur303121 (Rajasthan) 2.NMIMS, School of Pharmacy and Technology Management, Shirpur Maharashtra India ABSTRACT Tuberculosis is a ubiquitous, highly contagious chronic granulamatous communicable bacterial infectious disease caused by Mycobacterium tuberculosis and other species of same genera. “Rifabutin” which is useful in the management of tuberculosis. Formulated Rifabutin in the form of solid lipid nanoparticle evaluated for their efficacy ex-vivo by checking for various interactions. Thus, physiological parameters like cellular uptake, MTT cytotoxicity assay and hemolytic toxicity of rifabutin loaded mannosylated solid lipid nanoparticles are determined and compared. The present work establishes the suitability of rifabutin loaded mannosylated solid lipid nanoparticles as a delivery system.

查看原文本刊更多论文

利法布汀负载固体脂质纳米颗粒的体外疗效

请引用这篇文章:Patel M等人，利法布汀负载固体脂质纳米颗粒的体外功效。美国医药技术研究杂志2019。利法布汀负载固体脂质纳米颗粒的体外疗效研究NIMS大学药学院，Sobha nagar新德里高速公路，斋浦尔303121(拉贾斯坦邦)摘要结核病是一种普遍存在的、高传染性的慢性肉芽肿性传染性细菌传染病，由结核分枝杆菌和其他同属细菌引起。“利福布汀”在结核病的治疗中很有用。以固体脂质纳米颗粒的形式配制利福布汀，通过检查各种相互作用来评估其体外功效。因此，生理参数，如细胞摄取，MTT细胞毒性试验和溶血毒性的利福布汀负载甘醇基化固体脂质纳米颗粒被确定和比较。目前的工作建立了利法布汀负载甘露糖基化固体脂质纳米颗粒作为递送系统的适用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of PharmTech Research

自引率

0.00%

发文量